NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BioRegen Biomedical (Changzhou) Co., Ltd.

BioRegen Biomedical (Changzhou) Co., Ltd.

Private
ChangzhouHealthcare & Life Scienceshttps://bioregenmed.com/

Last Round

IPO

Jul 3, 2026

Total Funding Raised

$7M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

BioRegen Biomedical (Changzhou) Co., Ltd. is a medical device company that develops and manufactures therapeutic biomaterials and regenerative medicine products, including hyaluronic acid-based gels for surgical applications.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Advanced Materials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

regenerative medicinebiomaterialsbioactive glasstissue engineeringbone graft substitutedermal fillerwound dressingbiotechmedical device manufacturertissue repairmedtechbiomedical engineeringhydrogel

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioRegen Biomedical (Changzhou) Co., Ltd. Comparables

Compare BioRegen Biomedical (Changzhou) Co., Ltd. with similar companies based on industry and business-model similarity.

BioRegen Biomedical (Changzhou) Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Beijing Bestlife Regenerative Medicine Technology Co., Ltd.
88%
Hangzhou Singclean Medical Products Co., Ltd.
82%
Shanghai Haohai Biological Technology Co. Ltd
81%

BioRegen Biomedical (Changzhou) Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOJul 3, 2026
StrategicFeb 1, 2021
Series DJun 1, 2016
Series CJun 7, 2013
Series BJan 1, 2011
Series A
Dec 1, 2008

BioRegen Biomedical (Changzhou) Co., Ltd. Investors

Notable investors and investment history

BioRegen Biomedical (Changzhou) Co., Ltd. investors
InvestorRounds
Orient Securities Capital Investment CompanyStrategic
F-Prime CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 3, 2026

    $15.14M raised in IPO round.

  • Apr 11, 2026

    Grew 57% QoQ from 7 to 11 employees.

BioRegen Biomedical (Changzhou) Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BioRegen Biomedical (Changzhou) Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BioRegen Biomedical (Changzhou) Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersChangzhou
Employee Range11
Year Founded2008
Last FundingJul 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.